利索-全球专利检索

  1. 登录
  2. 注册
发明公开
EP2687852A1 Method for diagnosing and treating chronic fatigue syndrome 审中-公开
Verfahren zur Diagnose und Behandlung des chronischenErschöpfungssyndroms

Method for diagnosing and treating chronic fatigue syndrome
摘要：
The present invention relates to a method for diagnosing CFS or a predisposition thereto in vitro which comprises determining the levels of CD25, CD69, NKp46 and CD57 biomarkers in CD56+CD16+ NK cells and comparing with a reference value wherein increased levels of said markers is indicative the subject suffers or is predisposed to suffering CFS. Likewise the invention relates to a kit comprising reagents for assaying the levels of CD25, CD69, NKp46 and CD57 in CD56+CD16+ NK cells and to the use of said kit for the diagnosis of CFS or of a predisposition thereto. In addition, the invention relates to a reagent for inhibiting the expression or activity of at least one biomarker selected from the group consisting of CD69, NKp46 and CD5 or to a reagent for inducing the expression or activity of at least one biomarker selected from CD25, CD57, CD56 and Ki67 for use in the treatment or prevention of CFS in a subject in need thereof. Finally the invention relates to a kit comprising a reagent for inhibiting or inducing a biomarker of the invention and to the use of said kit for the treatment or prevention of CFS.
摘要（中）：

本发明涉及用于诊断体外CFS或其易感性的方法，其包括测定CD56 + CD16 + NK细胞中CD25，CD69，NKp46和CD57生物标志物的水平，并与参考值进行比较，其中所述标记物的增加水平是指示性的 受试者遭受或倾向于患有CFS。 同样，本发明涉及包含用于测定CD56 + CD16 + NK细胞中CD25，CD69，NKp46和CD57水平的试剂的试剂盒，以及所述试剂盒用于诊断CFS或其易感性的用途。 此外，本发明涉及用于抑制至少一种选自CD69，NKp46和CD5的生物标志物的表达或活性的试剂，或涉及用于诱导至少一种选自CD25， CD57，CD56和Ki67，用于治疗或预防有需要的受试者中的CFS。 最后，本发明涉及包含用于抑制或诱导本发明的生物标志物的试剂以及所述试剂盒用于治疗或预防CFS的试剂盒。

信息查询
Global Dossier Espacenet
0/0